Oncologic outcomes and patient-reported quality of life in patients with oropharyngeal squamous cell carcinoma treated with definitive transoral robotic surgery versus definitive chemoradiation
Diane C. Ling(UPMC Hillman Cancer Center), Umamaheswar Duvvuri(City University of New York), Bhavana V. Chapman(UPMC Hillman Cancer Center), Dwight E. Heron(Bon Secours Mercy Health), Sushil Beriwal(University of Pittsburgh Medical Center), Peyman Kabolizadeh(MemorialCare Long Beach Medical Center), J. Kim(University of Pittsburgh Medical Center), Robert L. Ferris(University of Pittsburgh), Garret Choby(Mayo Clinic), D.A. Clump(UPMC Hillman Cancer Center), S. Kim(University of Pittsburgh Medical Center)
Cited by 107
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590